ArticleBMC biotechnology2011
Site-specific modification of ED-B-targeting antibody using intein-fusion technology.
Article in BMC biotechnology, 2011. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 20 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
20 citing papers in PubMed, 34 citations in OpenAlex.
- The evolving landscape of enzymatic technologies for precision synthesis of antibody-drug conjugates.Antibody therapeutics · 2026Review
- Generation of binder-format-payload conjugate-matrices by antibody chain-exchange.Nature communications · 2024Article
- Ultrasound Molecular Imaging of Bladder Cancer via Extradomain B Fibronectin-Targeted Biosynthetic GVs.International journal of nanomedicine · 2023Article
- Greatest Hits-Innovative Technologies for High Throughput Identification of Bispecific Antibodies.International journal of molecular sciences · 2020Review
- Human fibronectin extra domain B as a biomarker for targeted therapy in cancer.Molecular oncology · 2020Review
- An off-the-Shelf Approach for the Production of Fc Fusion Proteins by ProteinInternational journal of molecular sciences · 2020Article
- The crystal structure of the naturally split gp41-1 intein guides the engineering of orthogonal split inteins from cis-splicing inteins.The FEBS journal · 2020Article
- A mesophilic cysteine-less split intein for proteinProceedings of the National Academy of Sciences of the United States of America · 2019Article
- Improved protein splicing using embedded split inteins.Protein science : a publication of the Protein Society · 2018Article
- Enzyme-Based Labeling Strategies for Antibody-Drug Conjugates and Antibody Mimetics.Antibodies (Basel, Switzerland) · 2018Review
- Access to site-specific Fc-cRGD peptide conjugates through streamlined expressed protein ligation.Organic & biomolecular chemistry · 2016Article
- Site-Specifically Labeled Immunoconjugates for Molecular Imaging--Part 2: Peptide Tags and Unnatural Amino Acids.Molecular imaging and biology · 2016Review
- Design of a Split Intein with Exceptional Protein Splicing Activity.Journal of the American Chemical Society · 2016Article
- Methods to Make Homogenous Antibody Drug Conjugates.Pharmaceutical research · 2015Review
- Site-specific antibody-drug conjugates: the nexus of bioorthogonal chemistry, protein engineering, and drug development.Bioconjugate chemistry · 2015Review
- Site-specific functionalization of proteins and their applications to therapeutic antibodies.Computational and structural biotechnology journal · 2014Review
- Facile chemical functionalization of proteins through intein-linked yeast display.Bioconjugate chemistry · 2013Article
- Induction of innate and adaptive immunity by delivery of poly dA:dT to dendritic cells.Nature chemical biology · 2013Article
- Streamlined expressed protein ligation using split inteins.Journal of the American Chemical Society · 2013Article
- Unprecedented rates and efficiencies revealed for new natural split inteins from metagenomic sources.The Journal of biological chemistry · 2012Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 2 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundA promising new approach in cancer therapy is the use of tumor specific antibodies coupled to cytotoxic agents. Currently these immunoconjugates are prepared by rather unspecific coupling chemistries, resulting in heterogeneous products. As the drug load is a key parameter for the antitumor activity, site-specific strategies are desired. Expressed protein ligation (EPL) and protein trans-splicing (PTS) are methods for the specific C-terminal modification of a target protein. Both include the expression as an intein fusion protein, followed by the exchange of the intein for a functionalized moiety.
resultsA full-length IgG specific for fibronectin ED-B was expressed as fusion protein with an intein (Mxe GyrA or Npu DnaE) attached to each heavy chain. In vitro protocols were established to site-specifically modify the antibodies in high yields by EPL or PTS, respectively. Although reducing conditions had to be employed during the process, the integrity or affinity of the antibody was not affected. The protocols were used to prepare immunoconjugates containing two biotin molecules per antibody, attached to the C-termini of the heavy chains.
conclusionFull-length antibodies can be efficiently and site-specifically modified at the C-termini of their heavy chains by intein-fusion technologies. The described protocols can be used to prepare immunoconjugates of high homogeneity and with a defined drug load of two. The attachment to the C-termini is expected to retain the affinity and effector functions of the antibodies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.